As of Jul 31
| -0.16 / -0.34%|
The 11 analysts offering 12-month price forecasts for Tetraphase Pharmaceuticals Inc have a median target of 50.00, with a high estimate of 60.00 and a low estimate of 41.00. The median estimate represents a +5.15% increase from the last price of 47.55.
The current consensus among 12 polled investment analysts is to Buy stock in Tetraphase Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.